2024-04-01 15:08:10 ET
NRX Pharmaceuticals, Inc. (NRXP)
Q4 2023 Earnings Conference Call
April 1, 2024 08:30 ET
Company Participants
Matthew Duffy - Chief Business Officer
Jonathan Javitt - Founder & Chief Scientist
Stephen Willard - Chief Executive Officer
Richard Narido - Chief Financial Officer & Treasurer
Conference Call Participants
Tim Moore - EF Hutton
Ed Woo - Ascendiant Capital
Presentation
Operator
Good morning everyone and welcome to the NRx Pharmaceuticals, Inc. Fourth Quarter and Full Year 2023 Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
I will now turn the call over to Matthew Duffy, the Company's Chief Business Officer. Please go ahead.
Matthew Duffy
Thank you, Camilla [ph] and welcome everyone.
Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. Federal Securities Laws. These statements subject to risks and uncertainties and could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on is call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the preannounced press release issued Thursday, the company's Form 10-K filed Friday and the press release issued this morning, all of which may be accessed on the Investor page of the NRx Pharmaceuticals website....
Read the full article on Seeking Alpha
For further details see:
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript